A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

Queensland Children?s Hospital, South Brisbane

Columbia University Medical Center, New York

Hopital la Timone Enfants, Marseille

IRCCS Istituto G. Gaslini, Genoa

CHU Dijon Bourgogne Hôpital François Mitterand, Dijon

Carolina Institute for Development DisabilitiesUniversity of North Carolina/School of Medicine, Carrboro

Hospital Universitario Puerta De Hierro Majadahonda, Madrid

CHRU de Brest, Brest

Hospital Universitario de Navarra;Unidad de Neuropediatría, Pamploa

IRCCS Eugenio Medea, Conegliano Veneto (TV)

Rush Medical Center, Chicago

Groupe Hospitalier Necker Enfants Malades, Paris

Dr. Von Haunersches Kinderspital, München

Rady Children's Hospital - San Diego, San Diego

Multicare Institute for Research and Innovation, Tacoma

Boston Children's Hospital, Boston

Vanderbilt Children's Hospital, Nashville

Ospedale Pediatrico Bambino Gesù, Rome

Hospital Sant Joan de Deu, Esplugues de Llobregat · Barcelona

Corporacio Sanitaria Parc Tauli, Sabadell